Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

BCG Vaccine and Amyloid Levels in Healthy Adults

Start: January 9, 2021
End: December 2021
Enrollment: 50

What Is This Study About?

The Bacille Calmette-Gurin (BCG) vaccine is used to reduce risk of tuberculosis and some other bacterial and viral infections. Studies of adults receiving the BCG vaccine suggest that the vaccine may reduce the risk for Alzheimer's. This pilot study will test if the BCG vaccine affects the amount of amyloid, a protein associated with Alzheimer's disease, in people with no cognitive impairment. All participants will receive an initial vaccine dose by injection in the arm, followed by a booster dose one month later. Participants will also provide blood samples before vaccination and nine months later for researchers to measure levels of amyloid and immune cells.

Do I Qualify To Participate in This Study?

Minimum Age: 50 Years

Maximum Age: 80 Years

Must have:

  • No cognitive impairment
  • No BCG vaccination prior to study enrollment

Must NOT have:

  • Known allergy to the components of the BCG vaccine or serious adverse events to other vaccines
  • History of or suspected past Mycobacterium tuberculosis infection or other mycobacteria infection
  • Fever (>100 F) within 24 hours before study screening
  • Suspected active viral or bacterial infection
  • Any vaccination in the past four weeks or expected vaccination during the study period
  • Severely immunocompromised (e.g., HIV-1 infection, organ or bone marrow transplant recipient, treatment with oral or intravenous steroids, treatment with anti-cytokine therapies, currently receiving chemotherapy, low levels of white blood cells, etc.)
  • Cancer diagnosis (e.g., malignant tumor or lymphoma) within the past two years

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Mindful Diagnostics and Therapeutics, LLC

Source: ClinicalTrials.gov ID: NCT04449926

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health